1. Effectiveness of the SARS-CoV-2 mRNA Vaccines in Pregnant Women
- Author
-
Adeel A. Butt, Laith J. Abu-Raddad, Ali Nizar Latif, Peter Coyle, Abdullatif Al Khal, Anvar Hassan Kaleeckal, Huda Abdullah Hussain Saleh, Hiam Chemaitelly, Abdul-Badi Abou-Samra, and Roberto Bertollini
- Subjects
Pregnancy ,medicine.medical_specialty ,Vaccination Campaigns ,Referral ,Neonatal outcomes ,Obstetrics ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,medicine ,Disease ,medicine.disease ,business - Abstract
Pregnancy may increase the risk of adverse maternal and neonatal outcomes in SARS-CoV-2 infection. Effectiveness of SARS-CoV-2 vaccines in pregnant women is not known. Using a test-negative case-control study, we determined the vaccine effectiveness of mRNA vaccines in preventing confirmed SARS-CoV-2 infection in pregnant women at a national referral hospital, which handles > 75% of the deliveries in Qatar. Among 2,020 pregnant women who met the study criteria, 397 had a positive SARS-CoV-2 RT-PCR and 1,623 had a negative test. Vaccine effectiveness ≥ 14 days after the second dose was 67.7% (95%CI 30.5–86.9), while vaccine effectiveness ≥ 14 days after the first dose but before the second dose was 40.3% (95%CI 0.0-80.4). There were nine severe/critical disease cases, and no deaths in the PCR-positive pregnant women, all among unvaccinated. The mRNA vaccines provide high level of protection against documented SARS-CoV-2 infection, which supports including pregnant women in vaccination campaigns.
- Published
- 2021